The Forum | World Medical Innovation Forum - Gene and Cell Therapy
Boston
May 2–4, 2022

The Forum

The 2022 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy. 

Senior healthcare leaders from around the globe shape and debate the area of gene and cell therapy. Our shared belief: no matter the magnitude of change, responsible healthcare is centered on a shared commitment to collaborative innovation–industry, academia, and practitioners working together to improve patients’ lives.

May 2–4, 2022

Gene and cell therapy holds immense potential to advance the quality of patient care, reduce cost, and improve outcomes. Systemic complexity, however, can hinder the translation of breakthroughs to clinical care.

Our collective mission: finding solutions to the medical, operational, and economic challenges confronting GCT-driven care to ensure that patients, providers, and healthcare organizations benefit as soon as possible.

Who Attends

Pharma
Provider
Venture Capital
Medical Device

Investors

Identify new technologies that offer clinical promise. Get insight from clinicians on the medical, technological, and operational factors that drive clinical success. Calibrate your investment strategy with input from industry leaders.

Industry Leaders

Engage with peers from across the GCT and machine learning ecosystem. Meet other executives, decision-makers, and business leaders from health care, pharma, medical devices, and biotech.

Clinicians and Investigators

The one event where physician and clinical leaders connect with peers across the medical landscape. Attend plenary panels, networking events, and fireside chats to capture insight into how GCT and other technology is enhancing the care continuum.

Government Leaders

Join leaders from across the spectrum of government roles. Learn about the priorities of officials who are leading government agencies. 

Payers

Connect with the executives who are determining how gene and cell therapy will be reimbursed.

Attendees by Industry

0%

Life Sciences and Biotech

0%

Healthcare

0%

Gene and Cell Therapy

0%

Clinician, Investigator, Hospital Staff

0%

Venture and Investment

0%

Non-Profit, Government, Media

2021 GCT White Paper

With a handful of approvals and a triple digit pipeline, gene and cell therapies (GCT) are on the cusp of ushering in a transformation in therapeutics reminiscent to where we were with antibodies 25 years ago.

This summary is to highlight key issues and opportunities brought up by GCT leaders.

The Difference

Why You Need to Be a Part
There are a lot of health conferences out there. But how do you discern what’s a worthy one; what makes the Forum the one you should attend? Let us tell you.

Past Forums

The Forum has hosted many top-tier speakers since its inception. See the past keynoters, as well as access to videos of the panels.

2021 Steering Committee

Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS (2021 Co-Chair) 

Susan Slaugenhaupt, PhD, Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute; Professor, Neurology, HMS (2021 Co-Chair)

Ravi Thadhani, MD, CAO, Mass General Brigham; Professor, Medicine and Faculty Dean, HMS (2021 Co-Chair)

Luk Vandenberghe, PhD, Grousbeck Family Chair, Gene Therapy, MEE; Associate Professor, Ophthalmology, HMS (2021 Co-Chair)

Xandra Breakefield, PhD, Geneticist, MGH; Professor, Neurology, HMS

Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet, Professor of Neurosurgery, HMS

Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor, Neurology, HMS

Meredith Fisher, PhD, Partner, Mass General Brigham Innovation Fund

Jean-Francois Formela, MD, Partner, Atlas Venture

Pat Fortune, PhD, VP, Market Sectors, Mass General Brigham Innovation

Anna Greka, MD, PhD, Medicine, BWH; Associate Professor, Medicine, HMS

Reid Huber, PhD, Partner, Third Rock Ventures

Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor, Neurology and Neuroscience, HMS

J. Keith Joung, MD, PhD, RRobert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS

Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences

Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS

Dave Lennon, PhD, President, Novartis Gene Therapies

John Lepore, MD, SVP, Head of Research, GlaxoSmithKline

Marcela Maus, MD, PhD, Director, Cellular Immunotherapy, Cancer Center, MGH; Associate Professor of Medicine, HMS

Marie McDonnell, MD, Chief, Diabetes Section and Director, Diabetes Program, BWH; Lecturer on Medicine, HMS

Patricia Musolino, MD, PhD, Co-Director Pediatric Stroke and Cerebrovascular Program, MGH; Assistant Professor of Neurology, HMS

Chandra Ramanathan, PhD, Global Head, Pharma R&D Open Innovation, Bayer

Alfred Sandrock, MD, PhD, EVP, R&D and CMO, Biogen

Bastiano Sanna, PhD, EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals

Christine Seidman, MD, Director, Cardiovascular Genetics Center, BWH; Smith Professor of Medicine & Genetics, HMS

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA